Immunocore Holdings plc (IMCR) earnings date
Feb 24, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 62% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Fri, Nov 6, 2026 | before open | 37 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Wed, Feb 25, 2026 | before open | 56 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | before open | 37 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | before open | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients – Topline overall survival data expected second quarter of 2027 Promising Phase 1 data with KIMMTRAK plus brenetafusp to be presented as a late-breaking oral at SITC - Randomized Phase 2/3 DUET-UVEAL" exhibit |
| Q3 FY2026 | "With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients,” said Bahija Jallal, CEO of Immunocore." exhibit |
| Q3 FY2026 | "The Company expects to pay, in the fourth quarter of 2026, approximately $120 million in sales-related rebate accruals." exhibit |
| Q3 FY2026 | "The trial is event-driven and topline overall survival data is expected in the second quarter of 2027." exhibit |
| Q2 FY2026 | "The Company expects to pay, in the second half of 2026, approximately $120 million in sales-related rebate accruals." exhibit |
| Q2 FY2026 | "The Company expects to present Phase 1/2 data from both trials in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/IMCR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/IMCR
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/IMCR/"><img src="https://veritasdata.dev/embed/IMCR.svg" alt="IMCR earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/IMCR/)
Script
<script async src="https://veritasdata.dev/embed/IMCR.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/IMCR"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.